Effects of propranolol therapy in Moroccan children with infantile hemangioma

Lahrichi, Anissa; Hali, F.; Baline, K.; Fatoiki, F.Z. El; Chiheb, Soumiya; Khadir, K.

doi:10.1016/j.arcped.2018.09.002

Cited by 6 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the authors concluded that the use of oral propranolol is well tolerated, effective, and safe in the treatment of IH during the postproliferative phase [4,6,7]. According to the literature, the duration of treatment with systemic propranolol ranges from 1 to 16 months [3,11,12]. In our study, the duration of oral propranolol IH treatment introduced after the proliferative phase ranged from 6 to 24 months, with 15 months as a median duration of treatment.…”

Section: Discussionmentioning

confidence: 53%

“…Approximately 10% of IHs require treatment during the proliferative phase due to local complications, a life-threatening location, cosmetic issues, or functional risks [3][4][5][6][7]. In 2008, Léauté-Labrèze et al reported an incidental finding that propranolol could control dramatically the growth of IH.…”

Section: Discussionmentioning

confidence: 99%

“…In 2008, Léauté-Labrèze et al reported an incidental finding that propranolol could control dramatically the growth of IH. Subsequent studies were conducted and demonstrated that the drug was well tolerated and produced excellent results [6,10] The exact mechanism of oral propranolol treatment for IH has not been elucidated [1,3,4]. There are several proposed hypotheses, including vasoconstriction, decreased renin production, inhibition of angiogenesis, and stimulation of apoptosis.…”

Section: Discussionmentioning

confidence: 99%

“…Oral propranolol (OP) is an effective treatment for complicated IHs [1]. Its dosage, effectiveness, and adverse effects, as well as monitoring of treatment, have been widely described [3][4][5][6][7]. There is no consensus on the optimal duration of propranolol treatment for infantile hemangiomas, and factors related to response to propranolol treatment in infantile hemangiomas have not yet been addressed, especially in the northern Moroccan region [3].…”

Section: Introductionmentioning

confidence: 99%

“…Its dosage, effectiveness, and adverse effects, as well as monitoring of treatment, have been widely described [3][4][5][6][7]. There is no consensus on the optimal duration of propranolol treatment for infantile hemangiomas, and factors related to response to propranolol treatment in infantile hemangiomas have not yet been addressed, especially in the northern Moroccan region [3]. The purpose of this study was to evaluate the efficacy and safety of an oral propranolol solution administered for high-risk IHs in a Moroccan population of the minimum age of 6 months up to the maximum age of 24 months in order to analyze factors related to the response of propranolol treatment.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Untitled

2020

Our Dermatol Online

View full text Add to dashboard Cite

Background: There is no consensus on the optimal duration of propranolol treatment in complicated infantile hemangiomas (IHs), and factors related to its response have not yet been addressed, especially as it relates to the northern Moroccan region. Aim: We analyze the factors of good response of IH to propranolol treatment in a Moroccan population; thus, this study is the first to consider an undeveloped country. Methods: A descriptive and analytic study was conducted for 9 years in our department. The following parameters were analyzed: epidemiologic, therapeutic, and progressive, as well as the factors responsible for therapeutic response. Results: Propranolol treatment for 153 cases of IH was completed. With an average age of 7.9 months, a tuberous form was found in 50.3% of the cases, with 58.1% located on the face. Side effects were minor, and response was good to excellent in 95.6% of the cases. In a univariate analysis, children over 12 months and those with mixed hemangioma, as compared with those with a tuberous form, were less likely to exhibit an excellent response (OR = 0.18 with a 95% CI = 0.03-0.68; and OR = 0.80 with a 95% CI = 0.68-0.94). Excellent response was more prevalent in children treated for more than 6 months (47.8% vs. 11.8%; p < 0.001). Conclusion: Our study proves the safety and efficacity of propranolol as a treatment of IH. Excellent response was very much correlated with age, clinical form of IH, and the duration of treatment.

show abstract